EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026

Reuters03-25

EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026

EOM reported that it completed IND-enabling toxicology and dosing animal studies for EOM613 with no adverse drug-related toxic effects observed after 28 days of daily subcutaneous dosing.
Prior Phase I/IIa human trial results in hospitalized COVID-19 patients were previously presented, and the company said it plans an initial Phase II exploratory trial of EOM613 in Crohn’s disease.
The planned Crohn’s study is expected to enroll 15–20 patients and is intended to start in Q1 2026 at sites in New Brunswick and Lakewood, New Jersey.
EOM also said it plans to reactivate an IND for EOM613 in cancer cachexia with a proposed open-label Phase II study in Stage 4 cancer patients using daily dosing for 26 weeks.
For EOM147, the company said specialized nonclinical ocular studies are anticipated to begin in Q1 2026, with Phase I/II trials planned in retinal vein occlusions in the US and diabetic retinopathy in Mexico and India if results support progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EOM Pharmaceutical Holdings Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622090351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 02:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622090351","market":"fut","top_or_hot":-1,"title":"EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          EOM reported that it completed IND-enabling toxicology and dosing animal studies for EOM613 with no adverse drug-related toxic effects observed after 28 days of daily subcutaneous dosing.\n        </li>\n<li>\n          Prior Phase I/IIa human trial results in hospitalized COVID-19 patients were previously presented, and the company said it plans an initial Phase II exploratory trial of EOM613 in Crohn’s disease.\n        </li>\n<li>\n          The planned Crohn’s study is expected to enroll 15–20 patients and is intended to start in Q1 2026 at sites in New Brunswick and Lakewood, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>.\n        </li>\n<li>\n          EOM also said it plans to reactivate an IND for EOM613 in cancer cachexia with a proposed open-label Phase II study in Stage 4 cancer patients using daily dosing for 26 weeks.\n        </li>\n<li>\n          For EOM147, the company said specialized nonclinical ocular studies are anticipated to begin in Q1 2026, with Phase I/II trials planned in retinal vein occlusions in the US and diabetic retinopathy in Mexico and India if results support progression.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EOM Pharmaceutical Holdings Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 02:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          EOM reported that it completed IND-enabling toxicology and dosing animal studies for EOM613 with no adverse drug-related toxic effects observed after 28 days of daily subcutaneous dosing.\n        </li>\n<li>\n          Prior Phase I/IIa human trial results in hospitalized COVID-19 patients were previously presented, and the company said it plans an initial Phase II exploratory trial of EOM613 in Crohn’s disease.\n        </li>\n<li>\n          The planned Crohn’s study is expected to enroll 15–20 patients and is intended to start in Q1 2026 at sites in New Brunswick and Lakewood, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>.\n        </li>\n<li>\n          EOM also said it plans to reactivate an IND for EOM613 in cancer cachexia with a proposed open-label Phase II study in Stage 4 cancer patients using daily dosing for 26 weeks.\n        </li>\n<li>\n          For EOM147, the company said specialized nonclinical ocular studies are anticipated to begin in Q1 2026, with Phase I/II trials planned in retinal vein occlusions in the US and diabetic retinopathy in Mexico and India if results support progression.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EOM Pharmaceutical Holdings Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4zPyp5:1","article_id":"2622090351","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622090351","pubTimestamp":1774378523,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"EOM reported that it completed IND-enabling toxicology and dosing animal studies for EOM613 with no adverse drug-related toxic effects observed after 28 days of daily subcutaneous dosing.Prior Phase I/IIa human trial results in hospitalized COVID-19 patients were previously presented, and the company said it plans an initial Phase II exploratory trial of EOM613 in Crohn’s disease.The planned Crohn’s study is expected to enroll 15–20 patients and is intended to start in Q1 2026 at sites in New Brunswick and Lakewood, New Jersey.EOM also said it plans to reactivate an IND for EOM613 in cancer cachexia with a proposed open-label Phase II study in Stage 4 cancer patients using daily dosing for 26 weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","CPHI":"惠普森医药","IMUC":"ImmunoCellular疗法"},"translate_title":"EOM Pharmaceutical计划在2026年第一季度进行15-20名患者的EOM613 II期克罗恩病试验","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPHI":0.9,"IMUC":0.9},"content_text":"EOM Pharmaceutical plans 15-20-patient Phase II Crohn’s disease trial of EOM613 in Q1 2026\n    \n\n\n          EOM reported that it completed IND-enabling toxicology and dosing animal studies for EOM613 with no adverse drug-related toxic effects observed after 28 days of daily subcutaneous dosing.\n        \n\n          Prior Phase I/IIa human trial results in hospitalized COVID-19 patients were previously presented, and the company said it plans an initial Phase II exploratory trial of EOM613 in Crohn’s disease.\n        \n\n          The planned Crohn’s study is expected to enroll 15–20 patients and is intended to start in Q1 2026 at sites in New Brunswick and Lakewood, New Jersey.\n        \n\n          EOM also said it plans to reactivate an IND for EOM613 in cancer cachexia with a proposed open-label Phase II study in Stage 4 cancer patients using daily dosing for 26 weeks.\n        \n\n          For EOM147, the company said specialized nonclinical ocular studies are anticipated to begin in Q1 2026, with Phase I/II trials planned in retinal vein occlusions in the US and diabetic retinopathy in Mexico and India if results support progression.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EOM Pharmaceutical Holdings Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622090351","isCrawlerRequest":true}